SFOSF (Shanghai Fosun Pharmaceutical (Group) Co) Other Operating Expense : $864 Mil (TTM As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Other Operating Expense?

Shanghai Fosun Pharmaceutical (Group) Co's Other Operating Expense for the three months ended in Mar. 2025 was $1 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was $864 Mil.

Shanghai Fosun Pharmaceutical (Group) Co's quarterly Other Operating Expense increased from Sep. 2024 ($-456 Mil) to Dec. 2024 ($880 Mil) but then declined from Dec. 2024 ($880 Mil) to Mar. 2025 ($1 Mil).

Shanghai Fosun Pharmaceutical (Group) Co's annual Other Operating Expense increased from Dec. 2022 ($823 Mil) to Dec. 2023 ($913 Mil) but then declined from Dec. 2023 ($913 Mil) to Dec. 2024 ($876 Mil).

Shanghai Fosun Pharmaceutical (Group) Co Other Operating Expense Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Other Operating Expense Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Operating Expense

Get a 7-Day Free Trial

499.99

757.14

823.21

913.42

876.44

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Operating Expense	Get a 7-Day Free Trial															1.56	439.63	-455.86	879.88	0.83

Shanghai Fosun Pharmaceutical (Group) Co Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $864 Mil.

Shanghai Fosun Pharmaceutical (Group) Co Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (OTCPK:SFOSF) » Definitions » Other Operating Expense

Traded in Other Exchanges

02196:Hong Kong 08HH:Germany 08HH:Germany 600196:China

Address

No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website

https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.